JW Pharmaceuticals is surging intraday. The KOSDAQ-listed company rose as much as 30% from yesterday's close , trading around 2,990 won. The previous close: 2,300 won. Volume is well above average. Meanwhile, KOSPI is in the 6,600s and KOSDAQ near 820. The indexes are quiet. This move appears to be specific to this stock and the hair-loss treatment theme, not a market-wide event . The divergence is too wide. The gap between index moves and this stock's move suggests something affecting the entire sector. Why Now, JW Pharma? It started in June. Health and Welfare Minister Jung Eun-kyung said hair-loss treatment should no longer be viewed solely as a cosmetic concern. National Health Insurance coverage is under review. The rationale: the financial burden on younger adults. JW Pharma has a robust hair-loss portfolio: Monad (finasteride), Dutamoa (dutasteride), and Rogaine Foam topical, plus an in-development topical treatment for male-pattern baldness with a biotec...